Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)⢠Click on a phase to view related trials
A Phase 2 Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
- Conditions
- Esophageal CancerAdvanced or Metastatic Solid Tumors with a SMARCA4 Mutationnon-small cell lung cancer (NSCLC)
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- Prelude Therapeutics Inc.
- Target Recruit Count
- 7
- Registration Number
- 2024-516889-11-00
- Locations
- đşđ¸
Florida Cancer Specialists, West Palm Beach, Florida, United States
đşđ¸Karmanos Cancer Institute, Detroit, Michigan, United States
đşđ¸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
- Conditions
- Metastatic Solid TumorAdvanced Solid TumorNon-small Cell Lung CarcinomaSMARCA4 Mutation
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Prelude Therapeutics
- Target Recruit Count
- 104
- Registration Number
- NCT06560645
- Locations
- đşđ¸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
đşđ¸Brigitte Harris Cancer Pavilion, Detroit, Michigan, United States
đşđ¸Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Mantle Cell Lymphoma (MCL)Diffuse Large B-cell Lymphoma (DLBCL)Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)MDS/Myeloproliferative Neoplasm (MPN) Overlap SyndromeRichter's SyndromeT-cell LymphomaChronic Myelomonocytic Leukemia (CMML)
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- Prelude Therapeutics
- Target Recruit Count
- 86
- Registration Number
- NCT05665530
- Locations
- đşđ¸
City of Hope, Duarte, California, United States
đşđ¸American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
đşđ¸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
- Conditions
- Advanced Solid TumorMetastatic Solid TumorNon-small Cell Lung CancersSMARCA4 Gene Mutation
- Interventions
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Prelude Therapeutics
- Target Recruit Count
- 135
- Registration Number
- NCT05639751
- Locations
- đşđ¸
University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
đşđ¸UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
đşđ¸Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut, United States
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Breast CancerGlioblastomaHead and Neck Squamous Cell CarcinomaNon-small Cell Lung CancersMalignant MesotheliomaSarcomaEndometrial Cancer
- Interventions
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Prelude Therapeutics
- Target Recruit Count
- 22
- Registration Number
- NCT05538572
- Locations
- đşđ¸
Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut, United States
đşđ¸AdventHealth Medical Group Oncology Research at Celebration, Celebration, Florida, United States
đşđ¸Miami Cancer Institute, Miami, Florida, United States
- Prev
- 1
- 2
- 3
- Next
News
Prelude Therapeutics' PRT3789 Shows Promise in SMARCA4-Mutated Cancers
⢠Prelude Therapeutics' PRT3789 demonstrated anti-tumor activity in SMARCA4-mutated NSCLC and esophageal cancer patients during Phase 1 dose escalation. ⢠The Phase 1 trial of PRT3789 showed the drug was generally well-tolerated, with no dose-limiting toxicities or study drug-related serious adverse events. ⢠The company aims to confirm the biologically active dose of PRT3789 by year-end and advance monotherapy and docetaxel combination studies. ⢠Preclinical data suggests that dual SMARCA2/4 degraders attached to antibodies could expand treatment possibilities beyond SMARCA4 mutations.